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Introduction: The Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System for the Treatment of
Thoracic Aortic Aneurysms (VALOR) trial findings noted superior 30-day and 1-year outcomes of the Talent thoracic
endograft (Medtronic Vascular, Santa Rosa, Calif) compared with surgical repair of descending thoracic aneurysms
(DTAs). Data from 195 prospective thoracic endovascular aneurysm repair (TEVAR) patients treated with the Talent
device and 189 retrospective controls undergoing open surgical repair (OSR) from three centers of excellence were
included in the trial after completion of TEVAR enrollment and compared. Such comparisons are biased by baseline
differences among TEVAR vs OSR, however, propensity score (PS) analysis can reduce bias and validate such
comparisons.
Methods: Logistic regression was used to generate a PS (range, 0-1) to identify baseline characteristics more likely in
TEVAR. The PS estimated the probability that any patient would undergo TEVAR (eg, a PS of 0.99 represents a 99%
chance a patient belongs to TEVAR). PSs were then generated for all patients, and TEVAR and OSR patients were
divided into tertiles based on the PS to reduce up to 80% of inherent bias. Outcomes from themiddle tertile (T2), patients
equally likely (midrange PS) to be in TEVAR or OSR and therefore best matched, were compared using regression
analysis and were also compared with the outcomes in the overall trial group.
Results: Correlates of membership in TEVAR were smaller aneurysm (P < .001), anticoagulants (P < .01), no previous
abdominal aortic aneurysm (AAA) repair (P < .01), no peripheral vascular disease (P  .001), statin use (P  .002),
aspirin use (P  .002), older age (P  .028), race (P  .007), male gender (P  .02), and heart failure (P  .035). T2
included 68 TEVAR (PS, 0.58  0.2) and 67 OSR patients (PS, 0.46  0.2). VALOR overall reported differences in
aneurysm size (56 mm TEVAR vs 69 mm open) and prior AAA repair (19% TEVAR vs 37% open), and this adjusted to
no differences in T2 patients. In the well-matched T2 cohort, TEVAR patients had similar 30-day mortality (0% vs 3%
OSR; P .2) and improved 1-year aneurysm-related mortality rates (0% TEVAR vs 8%OSR; P .05) compared with the
OSR patients. This finding was in concurrence with the VALOR trial reporting similar benefit in TEVAR patients. The
all-cause 1-year mortality showed a favorable trend for TEVAR in the VALOR trial; however, in T2 patients, 1-year
all-cause mortality was similar in both groups of patients (17% TEVAR vs 15% OSR; P  .8). Age (P  .01), history of
cerebrovascular accident (P < .05), antiarrhythmia medication (P  .04), and renal disease (P < .03) independently
predicted all-cause and aneurysm-related mortality by regression analysis.
Conclusions: PS analysis is an important tool for elimination of bias inherent when retrospective controls are used. Its
application to VALOR validates the long-term benefit in aneurysm-related mortality conferred by TEVAR in patients
undergoing endovascular DTA repair. ( J Vasc Surg 2011;54:22-9.)
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cThe Evaluation of the Medtronic Vascular Talent Tho-
racic Stent Graft System for the Treatment of Thoracic
Aortic Aneurysms (VALOR) trial recently reported the
safety and efficacy of the Medtronic Vascular (Medtronic
Vascular, Santa Rosa, Calif) Talent thoracic stent graft
(TEVAR) system for the treatment of descending thoracic
aortic aneurysms (DTAs).1 A fourfold reduction in 30-day
mortality, a twofold reduction in major adverse events, and
improved 1-year aneurysm-related mortality (ARM) for
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22atients undergoing DTA treatment with TEVAR com-
ared with open surgical repair (OSR) was noted.1 The
ALOR trial, however, was compromised in design be-
ause it was originally approved by the U.S. Food and
rug Administration (FDA) as a single-arm trial wherein
atients treated with TEVAR were prospectively en-
olled according to predetermined inclusion and exclu-
ion criteria. After accrual of prospective TEVAR patient
ata and upon presentation of the safety and efficacy data
o the FDA for device approval, a mandate for open
urgical controls was issued. Patients undergoing OSR
ere then included, after enrollment of TEVAR patients,
rom the prospectively maintained databases of three
enters of excellence in the treatment of DTA. The OSR
ontrol group therefore included retrospectively derived
atient outcomes data that were subjected to the inclu-
ion and exclusion criteria applied to the originally de-
igned single-arm TEVAR group. Comparisons thus
ade between the TEVAR and OSR groups and the
onclusions derived from such unmatched and tempo-
ally disparate groups of patients may be invalid as a
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Volume 54, Number 1 Patel et al 23result of inherent biases in the data and unforeseen
differences in the patient groups.
In light of the recent single-center2-8 and multicenter
data9,10 espousing the benefit of TEVAR for the treatment
of DTA and overall surgeon and public perceptions about
the benefits of “less invasive surgery,” completion of a
prospective randomized trial to generate level I data for the
treatment of DTA is nearly impossible. As such, a number
of recent pivotal device trials have resorted to the use of a
large proportion (50%) of retrospective patients as open
surgical controls in trial design and conclusions.11,12 Such
trials may be inherently biased by design and necessity;
however, statistical methods may be applied to such poten-
tially biased data to achieve meaningful conclusions.
Propensity score (PS) analysis has been applied to large
sets of nonrandomized data to model the selection process
of randomization and adjust for differences in background
characteristics leading to bias reduction.13 The goal of this
study was to evaluate the validity of the VALOR trial
outcomes by using PS analysis to define a well-matched
cohort of TEVAR and OSR patients for comparison of
outcomes.
METHODS
The VALOR trial was a prospective multicenter, non-
randomized study evaluating the safety and efficacy of
TEVAR in the treatment of DTA. The study reported the
30-day and 12-month outcomes of 195 TEVAR patients
and 189 OSR controls.1 TEVAR patients were prospec-
tively recruited fromDecember 2003 until June 2005 from
38 institutions. TEVAR group inclusion criteria included
Society of Vascular Surgery (SVS) class 0, 1, or 2, thoracic
aortic aneurysm size 5 cm or greater than two times the
diameter of nonaneurysmal aorta, proximal and distal aortic
diameters of 18 to 42 mm, and a minimal 20-mm proximal
and distal seal zones. Numerous anatomic and medical
exclusion criteria were reported by Fairman et al.1
The OSR controls were retrospectively included into
the trial and were derived from prospectively maintained
databases of patients undergoing open repair of DTA from
the Cleveland Clinic Foundation (CCF), the Hospital of
the University of Pennsylvania (UniversityPenn), and Mas-
sachusetts General Hospital (MGH). Patients treated for
localized aneurysms of the DTA between 1990 and 2005,
meeting inclusion and exclusion criteria applied to the
TEVAR group and with 1-year follow-up data, were in-
cluded in the OSR group. Anatomic inclusion criteria in-
cluded all fusiform DTA5 cm in size with a proximal and
distal aortic neck such that the proximal anastomosis would
be distal to the left subclavian artery and the distal anasto-
mosis would be placed cephalad to the celiac artery. A total
of 73 patients were included from CCF, 50 from Universi-
tyPenn, and 66 from MGH. Data provided from institu-
tional registries were internally validated and audited by
institution-specific protocols.
PS analysis was performed as previously described using
baseline clinical features and patient demographics (covari-
ates; Table I) reported in the VALOR trial.13,14 Nonparsi- tonious logistic regression analysis was performed in
hich being a member of the TEVAR group was the
ependent variable and the covariates listed in Table I were
ndependent variables. A PS ranging in value from 0 to 1
as generated for every patient, whether a TEVAR or OSR
atient, defining the probability that that individual patient
ould be part of the TEVAR group rather than in the OSR
roup given baseline clinical features of that individual. A
atient with a PS close to 1 would therefore be highly likely
o be a member of the TEVAR group, and a patient with a
S close to 0 would be highly likely to be a member of the
SR group. A patient with a PS close to 0.5 would be
qually likely to be a TEVAR or OSR patient. All patients
ere stratified into tertiles based on PS with the tertiles and
espective PS score ranges as follows: tertile 1 (T1), with PS
alues of 0.0 to 0.33; tertile 2 (T2), with PS values of 0.34
able I. Baseline clinical features of VALOR trial
atients
ariablea
TEVAR
(n  195)
OSR
(n  189)
ge, years 70  11 70  9
ale gender 115 (59) 99 (52)
AA size, mm 56  11b 69  12b
onwhite race 33 (17) 12 (6)
lood pressure, mm Hg
Systolic 132  21 136  19
Diastolic 74  12 79  12
troke (CVA) 19 (10) 25 (13)
enal insufficiency 34 (17) 30 (16)
yocardial infarction 27 (14) 39 (21)
ongestive heart failure 17 (9) 21 (11)
ypertension 170 (87) 168 (89)
ABG 20 (10) 25 (13)
OPD 72 (37) 80 (42)
obacco use 150 (77) 144 (76)
iabetes 31 (16) 16 (8)
VD 32 (16) 70 (37)
edications
Acetylsalicylic acid 101 (52)b 49 (26)b
Anticoagulants 32 (16) 12 (6)
ACE inhibitors 78 (40)b 52 (28)b
-blockers 128 (66) 122 (65)
Calcium antagonists 63 (32) 63 (33)
Antiarrhythmics
Class I 1 (0.5) 5 (3)
Class III 12 (6) 1 (0.5)
Digitalis 12 (6) 15 (8)
Vasodilators 27 (14)b 10 (5)b
Statins 101 (52)b 42 (22)b
AA
Prior AAA 37 (19) 70 (37)
Prior AAA repair 4 (2) 52 (28)
AA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme;
ABG, coronary artery bypass grafting; COPD, chronic obstructive pulmo-
ary disease; CVA, cerebrovascular accident; OSR, open surgical repair;
VD, peripheral vascular disease; TAA, thoracic aortic aneurysm; TEVAR,
horacic endovascular aneurysm repair.
Continuous data are mean  standard deviation; categoric data are
umber (%).
Values represent statistical differences (P  .05) between the TEVAR and
SR groups.o 0.66; and tertile 3 (T3), with PS values of 0.67 to 1.0.
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duce bias by up to 80%.15 Further stratification into groups
of four or five would theoretically reduce bias further;
however, this was not feasible due to patient imbalances in
T1 (12 TEVAR vs 115 OSR) and T3 (119 TEVAR vs 7
OSR) patients.
The clinical features of OSR and TEVAR patients
within each tertile were compared. Given the disparate
OSR and TEVAR patient numbers in T1 and T3, further
outcomes analysis of 30-day mortality, 1-year ARM, and
1-year all-cause mortality (ACM) was performed using
patients from T2, which includes 64 TEVAR and 67 OSR
patients.
All clinical features and demographic data are presented
as the number in each category and the percentage this
number represents. All mean data are presented with the
standard deviation. Kaplan-Meier analysis was used to eval-
uate freedom from ARM or ACM over time. The log-rank
test for the equality of the survival distribution curves was
used to evaluate for differences in ACM and ARM between
TEVAR and OPEN. Nonparsimonious logistic regression
analysis was used to generate the PS for each patient.
Multivariate regression analysis was performed after adjust-
ment for PS alone and with PS and covariates to identify
independent predictors of ARM or ACM. Odds ratios
(ORs) and 95% confidence intervals (CIs) are presented.
An independent statistician used SAS 9.1 software (SAS
Institute, Cary, NC) to perform the statistical analysis. A
two-sided P  .05 was considered statistically significant.
RESULTS
The baseline clinical features and patient demographics
for the VALOR trial are presented in Table I. TEVAR
patients were more likely to have a smaller TAA size, less
likely to have a prior AAA or previous AAA repair, and were
more likely to be taking aspirin, angiotensin-converting
enzyme inhibitors, vasodilators, and statins, as previously
reported.1 We used logistic regression with inclusion into
TEVAR as the dependent variable and the covariates as
independent variables, to generate coefficients for the pro-
pensity equation (Table II). The covariates most likely to
predict membership in TEVAR (by 2 analysis) were lower
TAA size (P .0001), use of anticoagulants (warfarin; P
.0005), no history of AAA repair (P .0008), no history of
peripheral vascular disease (PVD; P .0010), use of statins
(P  .0017), use of aspirin (P  .0022), older age (P 
.028), race (P  .0066), gender (P  .0207), and conges-
tive heart failure (P  .0352). The coefficient and the
presence of the noted covariate were used to generate a PS
for every patient in the study.
As previously noted, patients were stratified into tertiles
based on PS, and TEVAR and OSR patients in each tertile
were compared. The distribution of TEVAR and OSR
patients in each tertile and their mean PS are presented in
Table III. The distribution of patients in T1 and T3 was
uneven, and clinical features were disparate, making mean-
ingful comparisons unlikely. T2 patients were evenly dis- rributed in number and were well matched, with no differ-
nces in demographics and clinical features (Table IV).
The 30-day mortality and 1-year ARM rates in T2
EVAR patients were lower than for T2 OSR patients,
imilar to the VALOR trial results (Table V). The VALOR
rial reported no significant difference in 1-year ACM, with
trend favoring TEVAR (P  .1); however, in well-
atched T2 patients, TEVAR andOSR patients had similar
ates of ACM (Table V). The ARM and ACM survival
urves for T2 patients are presented in Figs 1 and 2,
espectively. The unadjusted OR for ARM favored patients
reated with TEVAR (0.24; 95% CI, 0.01-0.61; P .002).
he propensity-adjusted OR for ARM trended in favor of
EVAR (0.48; 95% CI, 0.14-1.7; P .13). The unadjusted
OR, 0.73; 95% CI, 0.43-1.2; P  .23) and propensity-
djusted (OR, 1.4; 95% CI, 0.63-2.9; P  .43) ORs for
CM revealed no differences between TEVAR and OSR.
fter adjustment for PS, independent predictors of ARM
ncluded previous cerebrovascular accident (CVA; P  .01),
se of an antiarrhythmia medication (P  .04), and renal
isease (P  .03). Independent predictors of ACM included
ge (P  .01), previous CVA (P  .002), use of an antiar-
able II. Coefficients of the propensity score equation
Variable Score
Age in years 0.0493a
Male gender 0.7550a
TAA size –0.1351a
Nonwhite race 1.4472a
Blood pressure
Systolic –0.00257
Diastolic –0.0134
Stroke (CVA), Y/N –0.2359
Renal insufficiency, Y/N 0.7870
Miocardial infarction, Y/N 0.1814
Congestive heart failure, Y/N –1.5157a
Hypertension, Y/N –0.0251
CABG, Y/N –0.2263
COPD, Y/N 0.0301
Tobacco use, Y/N 0.3374
Diabetes, Y/N 0.2223
PVD, Y/N –1.3620a
Medications, Y/N
Acetylsalicylic acid 1.1113a
Anticoagulants 2.0690a
ACE inhibitors 0.1765
-blockers –0.3831
Ca antagonists –0.5586
Antiarrhythmics
Class I –1.8652
Class III 1.3574
Digitalis –0.3255
Vasodilators 0.4167
Statins 1.1168a
Concurrent AAA –0.5579
Prior AAA repair –2.6293a
AA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme;
ABG, coronary artery bypass grafting;COPD, chronic obstructive pulmonary
isease; CVA, cerebrovascular accident; PVD, peripheral vascular disease;
Coefficients aremost likely to predict inclusion into the TEVARgroup (P .05).hythmia medication (P .04), and renal disease (P .02).
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The VALOR trial was initially designed and executed as
a single-armed prospective trial of TEVAR with a historical
OSR control group. The FDA considered the historical
controls specified as the comparator to the single-arm trial
inadequate.Medtronic therefore proposed and obtained an
OSR control group from three centers of excellence of
Table III. Distribution of thoracic endovascular aneurysm
tertile
Variable
Tertile 1
TEVAR OSR T
Patients, No. 12 115
Mean PS 0.17  0.08 0.06  0.06 0.58
PS, Propensity score.
Table IV. Baseline clinical features of tertile 2 patients
Variablea
TEVAR
(n  64)
OSR
(n  67)
Age 68  12 69  9
Male gender 37 (58) 35 (52)
TAA size 61  9 63  6
Nonwhite race 4 (6) 5 (7)
Blood pressure
Systolic 140  20 140  17
Diastolic 75  13 78  11
Stroke (CVA) 9 (14) 9 (13)
Renal insufficiency 8 (13) 6 (9)
Myocardial infarction 9 (14) 10 (15)
Congestive heart failure 4 (6) 3 (4)
Hypertension 53 (83) 57 (85)
CABG 8 (13) 6 (9)
COPD 27 (42) 29 (43)
Tobacco use 47 (73) 46 (69)
Diabetes 6 (9) 11 (16)
PVD 11 (17) 13 (19)
Medications
Acetylsalicylic acid 23 (36) 16 (24)
Anticoagulants 6 (9) 5 (7)
ACE inhibitors 25 (39)b 16 (24)b
-blockers 39 (61) 38 (57)
Calcium antagonists 18 (28) 13 (19)
Antiarrhythmics
Class I 0 0
Class III 2 (3) 0
Digitalis 6 (9) 5 (7)
Vasodilators 6 (9)b 1 (1)b
Statins 22 (34) 20 (30)
Concurrent AAA 15 (23) 10 (15)
Prior AAA repair 1 (2) 2 (3)
AAA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme;
CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmo-
nary disease; CVA, cerebrovascular accident; OSR, open surgical repair;
PVD, peripheral vascular disease; TAA, thoracic aortic aneurysm; TEVAR,
thoracic endovascular aneurysm repair.
aContinuous data are mean  standard deviation; categoric data are
number (%).
bValues represent statistical differences (P  .05) between the TEVAR and
OSR groups.approximately the same size as the study cohort. The furgical control arm was subjected to the same inclusion
nd exclusion criteria as the VALOR trial patients. Com-
arative analyses of such nonrandomized groups may be
ffected by selection and observational biases as well as
aseline differences in the populations being studied. The
tatistical methodology of PS analysis has been validated
nd successfully applied to a variety of clinical data sets to
acilitate bias reduction and strengthen study conclu-
ions.13-17 PS analysis was therefore agreed to between
edtronic and the FDA after the VALOR trial, and part of
his analysis was included in the initial postmarket analysis
ubmission.
PS analysis depends on adjustment for all potentially
rognostic characteristics and is therefore limited by the
vailability of such data for both groups. Unlike a random-
zed trial, bias reduction using PS analysis can thus be
ompromised by missing data or unmeasured characteris-
ics in one or both groups. The availability of measured data
as close to complete for all characteristics in the VALOR
tudy. Other characteristics that have been reported to
ffect clinical outcomes (eg, such as surgeon or hospital
olume), clinical presentation, operative characteristics (eg,
lamp times or use of surgical adjuncts), type of anesthetic,
nd preoperative functional status were not evaluated in the
ALOR trial and pose the major limitation to our propen-
ity analysis.
Propensity matching can be performed in numerous
ays, such as direct matching of patients based on PS value
n very large data sets or, as in our study, by stratifying the
wo patient cohorts using ranges of PS values. The stratifi-
ation may result in small numbers of patients in one
reatment group or the other in the highest and lowest
trata. When the latter occurs, it is necessary to reduce the
umber of strata to get the number into an acceptable
ange. Reducing the number of strata reduces the amount
f bias reduction, which was necessary in our analysis and
oses another limitation of our study.
The goal of our study was to evaluate the results of the
ALOR trial using patients whose clinical, demographic,
nd anatomic features were well matched by the PS. Our
ropensity-matched TEVAR andOSR patients were similar
ith respect to age, sex, and baseline demographics, with
he exception of differences in use of angiotensin-converting
nzyme inhibitors and vasodilators. The previously noted
ifferences in aneurysm size, aspirin use, statin use, and
oncurrent AAA or previous AAA repair were all corrected
air (TEVAR) and open surgical repair (OSR) patients by
Tertile 2 Tertile 3
OSR TEVAR OSR
67 119 7
.17 0.46  0.16 0.94  0.06 0.89  0.04rep
EVAR
64
 0or by propensity matching. Propensity analysis therefore
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trial patients for which 30-day mortality and 1-year ARM
and ACM were evaluated.
Our matched patient cohort (T2 TEVAR vs OSR)
showed no statistically significant difference in (procedural)
mortality for TEVAR for DTA over that of patients under-
going open surgical repair. The low event rate for 30-day
mortality (0 for TEVAR and 2 for OSR) in this matched
cohort resulted in an absence of a statistical difference;
Table V. Mortality rates in VALOR (all patients) and tert
Mortality
VALOR trial patients
TEVAR, No. (%)
(n  195)
OSR, No. (%)
(n  189)
30-day 4 (2)a 12 (8%)a
ARM 6 (3)a 22 (12%)a
ACM 31 (16) 39 (21%)
ACM,All-cause mortality;ARM, aneurysm-relatedmortality;OSR, open sur
aStatistical differences (P  .05) between the TEVAR and OSR groups.
Fig 1. Kaplan-Meier curves plot freedom from aneurys
endovascular aneurysm repair (TEVAR) and open gro
represents survival in patients treated with TEVAR, and th
controls.
Month 0 2 4
Open surgical repair
Patients at risk 67 61 61
Proportion surviving 1 .93 .9
95% confidence interval — 0.86-0.99 0.86-0
TEVAR
Patients at risk 64 63 61
Proportion surviving 1 1 1
95% confidence interval — — —however, a difference might have been noted had the T2 oatient cohort been larger in size. Similarly, our own single-
enter comparative study of concurrently treated stent graft
s open surgical controls showed only a trend in favor of
mproved procedural mortality for TEVAR.6 The lack of a
ignificant benefit with respect to 30-day mortality in our
revious study may be have been related to the early (1996-
005) experience with TEVAR represented by that report,
he inclusion of aneurysms requiring urgent repair (15%),
nd most importantly, patient selection, because up to 30%
patients
Tertile 2 (PS-matched) patients
TEVAR, No. (%)
(n  68)
OSR, No. (%)
(n  67) P
1 0 (0%) 2 (3%) .2
1 0 (0%)a 5 (8%)a .05a
7 11 (17%) 10 (15%) .8
epair; PS, propensity score; TEVAR, thoracic endovascular aneurysm repair.
lated mortality for the fraction of the tertile 2 thoracic
urgical repair patients alive over time. The solid line
ss-hatched line represents the survival of the open surgical
6 8 10 12
59 59 58 57
.93 .93 .93 .93
0.86-0.99 0.86-0.99 0.86-0.99 0.86-0.99
58 54 52 51
1 1 1 1
— — — —ile 2
P
.0
.0
.1m-re
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Although this study did not validate it, most publications,
including more contemporary single-center comparative
reports, a recent meta-analysis, and recent multicenter
comparative trials are in agreement with VALOR that
TEVAR is associated with reduced procedural mortality
compared with OSR.11,12,18,19
The 1-year ARM in our matched patient cohort yielded
conflicting results. The Kaplan-Meier analysis of TEVAR
and OSR patients in T2 validated the VALOR findings
showing a statistically significant benefit of TEVAR in
reducing ARM. A statistically significant benefit in OR for
ARM was noted for TEVAR patients when using all
(VALOR) patients. However, the propensity-adjusted OR
for ARM only showed a trend in favor of TEVAR for
aneurysm-related 1-year survival. This discrepancy may be
explained by the small sample size resulting in a larger 95%
CI for the propensity-adjusted OR and loss of statistical
significance. One may argue that the adjusted OR may be
more reflective of the truth because adjustments were made
for baseline differences in the patient groups. The same
argument can be made in favor of survival differences
Fig 2. Kaplan-Meier curves plot freedom from all-cause
aneurysm repair (TEVAR) and open surgical repair patien
treated with TEVAR, and the cross-hatched line represen
Month 0 2 4
Open surgical repair
Patients at risk 67 61 61
Proportion surviving 1 .91 .9
95% confidence interval — 0.84-0.98 0.84-0
TEVAR
Patients at risk 64 63 61
Proportion surviving 1 0.98 .9
95% confidence interval — 0.95-1.0 0.90-1because the T2 patients were propensity matched; there- Tore, differences seen in the survival curves were already
djusted for by propensity matching.
The exclusion of patients with prior AAA repair from
ntry into the trial in the VALOR test group while a
ignificant number of OSR controls had undergone prior
AA repair was amajor criticism of the VALOR report. The
nclusion of more complicated open surgical cases may
ave increased ARM in the OSR group, thereby favoring
EVAR; however, after exclusion of patients with prior
AA repair, the 12-month ARM continues to favor TEVAR
97%  1% TEVAR vs 92  2% OSR; P  .49; data not
hown).
The benefit of TEVAR over OSR in reducing ARM has
een similarly variable in the literature. Our single-center
eries reported similar ARM in OSR and TEVAR patients;
owever, TEVAR patients were a higher surgical risk
roup, as discussed above.6 The TX2 (William Cook Eu-
ope, Bjaeverskov, Denmark) international multicenter piv-
tal trial reported no benefit of TEVAR with respect to
RM, whereas the TAG (W. L. Gore and Associates,
lagstaff, Ariz) multicenter pivotal trial showed a statisti-
ally significant benefit of TEVAR in reducing ARM.11,12
ality in the fraction of the tertile 2 thoracic endovascular
ve over time. The solid line represents survival in patients
survival of the open surgical controls.
6 8 10 12
59 59 58 57
.88 .88 .86 .85
0.80-0.96 0.80-0.96 0.78-0.95 0.77-0.94
58 54 52 51
.92 .87 .84 0.83
0.86-0.98 0.79-0.96 0.75-0.93 0.73-0.92mort
ts ali
ts the
1
.98
5
.0he benefit of TEVAR in reducing ARM in the GORE
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ARM in that trial, which included procedural mortality
associated with the index TEVAR procedure. Meanwhile,
the VALOR and TX2 trials both included mortality associ-
ated with secondary procedures in the calculation of ARM.
The benefit of TEVAR with respect to ARM is therefore
unresolved at this time and warrants a more uniform defi-
nition and further study.
In our propensity-matched T2 patients, 1-year ACM
was similar, with both TEVAR and OSR patients having
similar mortality of 17% and 15%, respectively. No differ-
ences in ACM between TEVAR and OSR were reported by
the TAG and TX2 pivotal trials.11,12 In addition, single-
center and multicenter registry studies reported similar
long-term survival in medically high-risk patients.6,10,18
The 5-year results of the TAG pivotal trial noted similar
ACM rates (40%) for TEVAR and OSR.20 Despite im-
proved periprocedural mortality and ARM in favor of TE-
VAR, the absence of benefit with respect to ACM reflects
the long-term mortality of elderly patients with DTA and
their associated comorbidities. The all-cause mortality
(15%/year) reported in our current study is similar to that
in previously reported retrospective and natural history
studies.21-23 TEVAR is not likely to affect improvements in
ACM of this patient population. In such patients, the
extensive comorbidities and limited long-term survival ar-
gue in favor of TEVAR, the least morbid approach, as the
primary modality for treatment of DTA when possible.
The VALOR trial data were used to identify indepen-
dent predictors of ACM and ARM after adjustment for the
PS. ACM was independently predicted by older age, previ-
ous history of CVA, use of antiarrhythmia medication, and
renal disease. ARM was independently predicted by history
of CVA, use of antiarrhythmia medication, and renal dis-
ease. These clinical features reflect a more medically unfit
patient population with death a more likely eventual out-
come in such patients. Dillavou et al24 reviewed the TAG
pivotal trial data, noting a higher mortality in men and in
those with symptomatic aneurysms. Data on independent
predictors of mortality associated with TEVAR are limited;
however, renal insufficiency has been noted to predict
30-day and long-term mortality in patients treated with
TEVAR.25,26 Whether the presence of such risk factors,
especially renal insufficiency, should be prohibitive in rec-
ommending treatment of DTA with TEVAR requires fur-
ther investigation.
Our study is limited by its small size of 64 TEVAR and
67 OSR patients; hence, the observation of 0% 30-day
mortality and 0% 1-year ARM in the TEVAR group likely
represents a selection bias or sampling error. Despite the
small size of the T2 group, the outcomes in our cohort
mirror that of the VALOR trial and the true rates of
procedural mortality and ARM likely lie somewhere in
between 0% and those reported in VALOR (2.1% 30-day
and 3.1% ARM). In support of our findings, the TAG and
TX2 pivotal trials similarly reported very lowmortality rates
of 2.1% 30-day and 3% ARM and 1.9% 30-day and 5.8%
ARM, respectively.11,12 More recently, the 5-year TAGrial outcomes were reported by Makaroun et al20 noting a
ignificant benefit with very low rates of ARM in TEVAR
atients (2.8% TEVAR vs 11.7%OSR; P .008) with up to
6 months of follow-up.20
One may argue that both of the other pivotal trials
ncluded a large number of retrospective open surgical
ontrols of up to 53% (TAG) and 73% (TX2) and may have
een similarly affected by biases as the VALOR trial. Our
urrent analysis validates the favorable findings of the
ALOR report with respect to the role of TEVAR in
anagement of DTA.Had the results of our analysis shown
he contrary, that TEVAR was inferior to OSR, further
tudy in the form of a prospective randomized controlled
rial would be feasible. Such a finding would also support
imitation of TEVAR use in patients at high-risk for open
urgery or those with reduced long-term survival; however,
his was not the case. Data from international registries10
eport low rates of procedural morbidity and rapid patient
ecovery, and because all currently available stent grafts for
se in the United States have long been approved for
uman use in other parts of the world, there exists a very
arge international experience supporting these findings.
urthermore, the conclusions of all three pivotal U.S. trials
oncur with one another and with many single-center
eports with respect to the clinical efficacy and relative
afety of TEVAR for the treatment of DTA, making
EVAR widely applicable to appropriately selected patients.
ONCLUSIONS
Using PS analysis, we have validated the findings of the
ALOR trial. All-cause mortality for patients with DTA is
naffected by the modality of treatment, whereas TEVAR
or the treatment of DTA may reduce periprocedural and
neurysm-related mortality. TEVAR should therefore be
he preferred modality for treatment of DTA in anatomi-
ally and medically suitable patients.
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